Go to Page # Page of 48

Developing Breakthrough Therapies in Nash & Mucopolysaccharidosis

 Frédéric Cren, Pierre Broqua PhD, Jean Volatier, Marie-Paule Richard MD
Description: Inventiva investment highlights for clinical stage biotech with a focus on oral small molecules for high unmet need in fibrosis, lysosomal storage disorders and oncology.
Views: 1149
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Inventiva
 ‐ More of their Presentations
Developing breakthrough therapies in
NASH and mucopolysaccharidosis
Corporate Presentation
April 2019

This document has been prepared by Inventiva (the "Company") solely for the purpose of this presentation. This presentation includes only summary information and does not purport to be
comprehensive. Any information in this presentation, whether from internal or from external sources, ... See more

Recent Presentations

Yalin Firinci
19 August, 2019

Regulatory Science for R&D Promotion

At present, the nation’s policy for Research and Development (R&D) promotion of innovative pharmaceuticals & improvement of environments for the R&D is formulated by Japanese gover

18 August, 2019
16 August, 2019